NCT04045392

Brief Summary

The purpose of this randomized clinical trial is to examine the effects of Mediterranean diet based intervention on inflammation and metabolic risk factors in overweight or obese postmenopausal women with breast cancer receiving adjuvant hormone therapy.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
78

participants targeted

Target at P25-P50 for not_applicable breast-cancer

Timeline
Completed

Started Aug 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 25, 2019

Completed
7 days until next milestone

Study Start

First participant enrolled

August 1, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 5, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2020

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2021

Completed
Last Updated

August 5, 2019

Status Verified

August 1, 2019

Enrollment Period

1 year

First QC Date

July 25, 2019

Last Update Submit

August 2, 2019

Conditions

Outcome Measures

Primary Outcomes (4)

  • Change in C-Reactive Protein (CRP) levels

    Blood will be drawn from the participants for assessment of CRP levels (mg/L)

    Baseline, 8 weeks

  • Change in fasting insulin levels

    Blood will be drawn from the participants for assessment of fasting insulin levels (mcIU/mL) after fasting for at least 8 hours

    Baseline, 8 weeks

  • Change in fasting glucose levels

    Blood will be drawn from the participants for assessment of fasting glucose levels (mg/dL) after fasting for at least 8 hours

    Baseline, 8 weeks

  • Change in lipid profile

    Blood will be drawn from the participants for assessment of total cholesterol, triglyceride, HDL-cholesterol, and LDL-cholesterol (mg/dL) after fasting for at least 8 hours

    Baseline, 8 weeks

Secondary Outcomes (4)

  • Change in body weight

    Baseline, 8 weeks

  • Change in fat mass measured by bioelectrical impedance analyzer

    Baseline, 8 weeks

  • Change in quality of life assessed by EORTC QLQ-C30 questionnaire

    Baseline, 8 weeks

  • Change in quality of life assessed by OP scale questionnaire

    Baseline, 8 weeks

Study Arms (2)

Mediterranean diet group

EXPERIMENTAL

Mediterranean diet with calorie restriction below 1,500 kcal per day.

Behavioral: Mediterranean diet

Conventional diet group

NO INTERVENTION

Conventional diet with calorie restriction below 1,500 kcal per day.

Interventions

Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.

Mediterranean diet group

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Breast cancer patients who are receiving adjuvant hormone therapy after diagnosed with breast cancer stage Ⅰ-Ⅲ and have completed cancer treatment including breast surgery and/or adjuvant chemotherapy, radiotherapy
  • Postmenopausal women
  • Body mass index (BMI) ≥23 kg/m2
  • Able to speak and read Korean
  • Able to comply with all required study procedures and schedule
  • Willing and able to give written informed consent

You may not qualify if:

  • Participants with cancer recurrence or metastasis
  • Participants with weight change more than 5kg in the previous 3 months
  • Participants with secondary causes of obesity, such as hypothyroidism
  • Participants with hepatic disease (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>3 x institutional upper limit of normal) or renal disease (serum creatinine \>2.0 mg/dL)
  • Participants with serious psychiatric illness, including bipolar disorder, schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation
  • Participants who are taking weight loss medications
  • Participants who are receiving systemic corticosteroid therapy
  • Participants with alcohol abuse or dependence

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Cho AR, Hong KW, Kwon YJ, Choi JE, Lee HS, Kim HM, Bae SJ, Ahn SG, Jeong J, Lee JW. Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial. Front Nutr. 2022 Jul 1;9:882717. doi: 10.3389/fnut.2022.882717. eCollection 2022.

MeSH Terms

Conditions

Breast NeoplasmsObesity

Interventions

Diet, Mediterranean

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diet, Plant-BasedDiet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor, Department of Family Medicine

Study Record Dates

First Submitted

July 25, 2019

First Posted

August 5, 2019

Study Start

August 1, 2019

Primary Completion

August 1, 2020

Study Completion

August 1, 2021

Last Updated

August 5, 2019

Record last verified: 2019-08